BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

EDP Biotech Corporation: New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials


9/16/2009 9:29:08 AM

KNOXVILLE, Tenn., Sept. 16 /PRNewswire/ -- Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker(TM) assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials. ColoMarker is the first assay of its kind to enable both early detection screening and patient management capabilities, presenting the potential to save time, money and, most importantly, lives.

Colon cancer is the second most prevalent cancer in the U.S., surpassed only by lung cancer. In 2009, nearly 150,000 new colon cancer cases will be confirmed and more than 55,000 people are projected to die from the disease.

ColoMarker's Preliminary Potential

The pre-clinical trials, conducted from January through August 2009, evaluated 2,370 freshly drawn serum samples. ColoMarker, which uses a proprietary biomarker developed by EDP, had an overall accuracy rate of 93 percent.

"The FOB test is not 'patient friendly,' meaning that most people either refuse to use the test or cannot collect the sample effectively," continued Jones. "ColoMarker is the first 'blood-based' assay that will simplify the whole process for both patients and doctors."

EDP has applied for patents on the reagents and assay, and is moving toward next steps for the commercialization of the test.

*The reported results for the FOB test were lower than seen in other studies. The patients used for the study may have caused this. The false positive rate on FOB for patients referred to a GI specialist is higher than seen for the general population. Even for this problematical patient set, the ColoMarker assay provided significantly better performance.

EDP Biotech Corporation




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES